1.10
-2.65%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Decoy Therapeutics
From its filings with the US Securities and Exchange Commission
Decoy Therapeutics is based in Houston, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DCOY. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $0.
We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP3ACT platform. Our IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning ("ML") and artificial intelligence ("AI") tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas. Utilizing our novel IMP3ACT platform that increases the drug development speed and reduce the complexity of variant synthesis, we aim to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, with the goal of becoming a fully integrated biopharmaceutical company at the forefront of this field. Through this approach, we intend to revolutionize the design, development, and commercialization of peptide conjugate therapeutics. We have no products approved for commercial sales and have not generated any revenue from product sales.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jan 2015
- Employees
- 11
- Website
- flex-pharma.com ↗
- Head office
- 2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. William McVicarIndependent Chairman of the Board, since 2017$74,944
- Mr. Mark RosenblumActing Chief Executive Officer, Chief Financial Officer, Executive Vice President$350,422
- Mr. David ArthurDirector, since 2019$734,450
- Ms. Tess BurlesonIndependent Director$57,944
- Mr. Arnold HanishIndependent Director$62,444
- Dr. Paul LammersIndependent Director$61,694
- Mr. Jonathan LieberIndependent Director$52,444
- Dr. Bruce MccreedyIndependent Director, since 2019$46,944
- Ms. Maureen McEnroeIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Decoy Therapeutics Inc employs 11 employees in Houston, Texas.
- Seclidemstat is a reversible LSD1 inhibitor in phase I for Ewing sarcoma.
- The company focuses on epigenetic causes of pediatric and solid tumors.
Weaknesses
- The company has only 11 employees and is a clinical-stage oncology firm.
- Seclidemstat is in phase I clinical study for Ewing sarcoma only.
- The firm has no other products besides Seclidemstat.
Opportunities
- Seclidemstat is being developed for prostate, breast, and ovarian cancers.
- The company targets unmet needs in pediatric and solid tumor cancers.
- Decoy Therapeutics Inc could expand its clinical studies in multiple cancer types.
Threats
- The company's IPO was on 29 January 2015, which may limit funding.
- Seclidemstat is only in phase I clinical study for Ewing sarcoma.
- The firm has no other products to mitigate risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.